News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Stephen Liu: Final anaysis of WJOG9717L
Photo from Stephen Liu/X
Aug 27, 2024, 22:13

Stephen Liu: Final anaysis of WJOG9717L

Stephen Liu shared a post on X:

“Final anaysis of WJOG9717L (phase II osimertinib +/- bevacizumab in EGFR NSCLC) JTO and JTO CRR.

Median PFS 20.2m with osimertinib alone, 22.1m with osimertinib and bevacizumab, no difference in 3y OS. Analysis by TP53 in ctDNA still showed no improvement.”

Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFRmutations: the WJOG9717L study.

Authors: Hirotsugu Kenmotsu, Kazuko Sakai, Keita Mori, Terufumi Kato, Shunichi Sugawara, Keisuke Kirita, Yasuto Yoneshima, Koichi Azuma, Kazumi Nishino, Shunsuke Teraoka, Ryo Koyama, Ken Masuda, Hidetoshi Hayashi, Ryo Toyozawa, Satoru Miura, Yuki Sato, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kazuto Nishio, and  Takahashi.

Stephen Liu

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Bevacizumab cancer EGFR Hidetoshi Hayashi Hirotsugu Kenmotsu JTO JTO CRR Kazuhiko Nakagawa Kazuko Sakai Kazumi Nishino Kazuto Nishio Keisuke Kirita Keita Mori Ken Masuda Koichi Azuma Nobuyuki Yamamoto NSCLC OncoDaily Oncology osimertinib Ryo Koyama Ryo Toyozawa Satoru Miura Shunichi Sugawara Shunsuke Teraoka Stephen Liu Terufumi Kato Toshiaki Takahashi TP53 WJOG9717L Yasuto Yoneshima Yuki Sato
Special Coverage
Blog
Nov 21, 2024, 06:52
Sylvester’s third annual Art is Medicine exhibit's new theme is "The Bridge to Bahia"
Blog
Nov 21, 2024, 06:49
OncoInfluencers to Follow on Social Media: Dr. Melvin L.K. Chua
Blog
Nov 21, 2024, 06:44
Hedley Lewis: Gratitude to all The Cows who participated in the Virgin Active South Africa Ride Joburg
Insight
Nov 21, 2024, 06:29
Sami Mansfield: What if improving metabolic health could reduce cancer risks and improve outcomes?
Blog
Nov 21, 2024, 06:27
Julie Gralow: Comprehensive Genomic Profiling Improves Precision Therapy Use And Patient Survival
Insight
Nov 20, 2024, 20:44
Baris Turkbey: Excited to announce NCI Molecular Imaging members presenting their research at RSNA2024
Blog
Nov 20, 2024, 20:38
Franklin Iheanacho: Changing treatment patterns for hepatocellular carcinoma
Insight
Nov 20, 2024, 20:27
HIPEC improves overall survival in recurrent epithelial ovarian cancer
Blog
Nov 20, 2024, 19:12
Medicaid Cancer Foundation at 1Ummah Annual Convention
Insight
Nov 20, 2024, 19:12
Sahar Mansour: Advancing Breast Microcalcification Detection with AI
Blog
Nov 20, 2024, 19:12
Reflecting on Progress and Partnerships in Lung Cancer Care – Sarah Cannon Research Institute
Blog
Nov 20, 2024, 19:12
Virtual tumor board on the management of a patient with Metastatic Squamous NSCLC - IASLC